Notice of 38th AGM to be held on 25th Sep 2026 at 03.00 p.m. through Video Conferencing/Other Audio Visual Means in accordance with the relevant circulars issued by the MCA and SEBI.

GODAVARI DRUGS LIMITED Regd. Off.:‘Mayfair’, S.P. Road, Secunderabad - 500 003. TS, India. Voice: +91-40-2784 9700/ 2784 2602/ 2784 4557 Email: info@godavaridrugs.com / Website: www.godavaridrugs.com To, Date: 01.09.2026 BSE Limited, P.J. Towers, Dalal Street, Mumbai – 400001 Unit: Godavari Drugs Limited (Scrip Code: 530317) Sub: Notice of the 38th Annual General Meeting and Annual Report for the Financial Year ended March 31, 2026 The Company informs that the 38th Annual General Meeting ("AGM") of the Company is scheduled to be held on Friday, September 25, 2026, at 03.00 p.m. through Video Conferencing / Other Audio-Visual Means, in accordance with the relevant circulars issued by the Ministry of Corporate Affairs and Securities and Exchange Board of India ("SEBI"). In terms of Regulation 34(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are submitting herewith the Annual Report of the Company for the financial year 2025-26 and the Notice of 38th AGM, which is being sent through electronic mode to those members whose e-mail addresses are registered with the Registrar & Share Transfer Agent / Depository Participants. Further, pursuant to Regulation 36(1)(b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, a letter providing the web-link of the Annual Report, being sent to those members who have not registered their e-mail address, is also attached and available on the Company’s website at https://godavaridrugs.com/annual-reports/ The Annual Report containing the Notice of 38th AGM is also uploaded on the Company’s website at www.godavaridrugs.com and the same shall also be available on the website of CDSL at www.evoting.nsdl.com Other relevant details with regard to the 38th AGM are as follows: Cut-off date for determining the eligibility of Friday, 18 September 2026 shareholders for remote e-voting or voting during the AGM Closure of Register of Members & Share From Saturday, September 19, 2026 to Friday, Transfer Books September 25, 2026 (both days inclusive) for the purposes of holding 38th AGM. Period of Remote e-voting to enable the The remote e-voting period will commence at 09:00 shareholders as on the cut-off date i.e., Friday, A.M. (IST) Tuesday, September 22, 2026, and end at September 18, 2026 to cast their votes on 5.00 P.M. (IST) on Thursday, September 24, 2026 proposed resolutions electronically This is for the information and records of the Exchange, Thanking you. Yours faithfully, For Godavari Drugs Limited Venkatesh Achanta Company Secretary & Compliance Officer Plant: A6/2, MIDC, Nanded – 431603, Maharastra, India. Email: nnd@godvaridrugs.com CIN: L24230TG1987PLC008016 ANNUAL REPORT FY 2025-26 From Molecule to Momentum Chemistry that Moves Forward YEARS OF CHEMISTRY. GODAVARI DRUGS LIMITED ANNUAL REPORT 2025-26 ANNUAL REPORT 2025-26 INDEX CORPORATE OVERVIEW Chairman’s Message 3 Board of Director’s 5 Corporate Information 6 Vision and Mission 7 About Our Company 8 Culture & People 9 Strategic Collaborations 10 Products 11 Research & Development Labs 14 Manufacturing Facility 15 Environment, Health & Safety 16 STATUTORY REPORTS Tracking of Finances 18 Notice 20 Director’s Report 35 Management Discussion & Analysis 51 Form No. MR-3 Secretarial Audit Report 65 Corporate Governance Report 69 FINANCIAL STATEMENTS Independent Auditor’s Report 96 Balance Sheet 107 Statement of Profit and Loss 110 Cash Flow Statement 112 Notes (Material Accounting Policies) 114 Godavari Drugs Limited INDEX GODAVARI DRUGS LIMITED ANNUAL REPORT 2025-26 CORPORATE OVERVIEW Chairman’s Message Dear Stakeholders, It is my pleasure to present to you the progress of Godavari Drugs Limited during FY 2025–26 and share our vision for the next phase of the Company’s growth. The year gone by has been one of transition and execution for your Company. Over the past few years, we have made significant investments in manufacturing infrastructure, product development, technology, and people. We are now entering a phase where these investments are beginning to translate into new products, new markets, and new business opportunities. Our facility for manufacturing Anti-HIV intermediates is currently under production trials and stabilization. The pharmaceutical industry continues to experience competition and pricing pressures, particularly in the API segment. At the same time, the global pharmaceutical supply chain is undergoing a structural shift, with customers increasingly looking for dependable manufacturing partners outside traditional sourcing geographies. We believe this changing environment presents meaningful opportunities for Indian manufacturers. Our strategy continues to focus on diversifying the Company beyond its established product portfolio. We intend to leverage our manufacturing infrastructure, technical capabilities, and experience in APIs and intermediates to pursue opportunities emerging in the pharmaceutical industry. We see considerable potential in building long-term CDMO and CMO partnerships with pharmaceutical companies looking for reliable, quality- focused, and cost-competitive manufacturing partners in India and around the globe. The new state-of-the-art manufacturing facility marks an important milestone in our growth journey. As we ramp up production at the new facility, we expect to progressively expand our product capabilities, improve manufacturing efficiencies, and cater to larger opportunities across domestic and international markets. GODAVARI DRUGS LIMITED ANNUAL REPORT 2025-26 Enhancing our international business remains an important pillar of our growth strategy. Continual efforts are being made to expand our presence across global markets and strengthen relationships with international customers. The ongoing China+1 movement and increasing emphasis on supply-chain resilience provide Indian API and intermediate manufacturers with significant opportunities. As we look ahead, our priorities are clear — commercialise new products, ramp up our new manufacturing capacities, grow exports, strengthen backward integration, and continue diversifying our product portfolio. We believe these initiatives can create multiple and sustainable growth drivers for Godavari Drugs Limited. The journey ahead will require patience, execution, and continued investment. However, we are confident that the capabilities and foundation built over the past few years position the Company well to pursue the opportunities emerging in the pharmaceutical industry. I would like to express my sincere appreciation to our employees for their dedication and contribution, to my colleagues on the Board for their guidance, and to our shareholders for their continued faith in the Company. I also extend my gratitude to our customers, suppliers, bankers, business partners, and all other stakeholders for their continued support and confidence in Godavari Drugs Limited. With a stronger foundation, a more diversified product portfolio, and new avenues for growth, we look forward to the future of our company with confidence and optimism. Ghanshyam Jaju Chairman Godavari Drugs Limited GODAVARI DRUGS LIMITED ANNUAL REPORT 2025-26 CORPORATE OVERVIEW Board of Director’s Mr. Ghanshyam Jaju Mr. Mukund Kakani MANAGING DIRECTOR CHAIRMAN A chemical engineer (B.Tech) from Osmania A commerce graduate with more than 40 University and holds an experience of more years of experience in business. He was than 40 years in the industry. He is one of earlier engaged in the family business of the promoters and Managing Director of the cotton ginning pressing industries and Company since its inception. He is overall in Oil Mills. He is a promoter Director of the charge of operations and development of Company and his the Chairman since the Company. inception. Mr. Mohit Jaju Mr. Dinesh Udpa WHOLETIME DIRECTOR & CFO NON EXECUTIVE INDEPENDENT DIRECTOR He is an engineer (BE) by qualification with He holds a Bachelor of Technology in e [Showing first 8,000 characters — download PDF for full document]